Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

他汀类药物治疗可降低AS+PsA患者的心血管风险和总死亡率

2016-11-14 MedSci MedSci原创

他汀类心血管死亡强直性脊柱炎银屑病关节炎
关注

根据美国风湿病学会年会上提交的调查结果显示，使用他汀类药物可以让强直性脊柱炎+银屑病关节炎患者的死亡率下降32%。 Amar Oza博士和同事们对2904例强直性脊柱炎(AS)+银屑病关节炎(PsA)患者进行了研究，研究他汀类药物对这类患者的生存益处。 平均随访时间为5.3年，他汀类使用者中死亡人数为271例；对照组5.15年的随访期间内，死亡人数为376例。他汀类药物使用组的死亡率为

根据美国风湿病学会年会上提交的调查结果显示，使用他汀类药物可以让强直性脊柱炎+银屑病关节炎患者的死亡率下降32%。

Amar Oza博士和同事们对2904例强直性脊柱炎(AS)+银屑病关节炎(PsA)患者进行了研究，研究他汀类药物对这类患者的生存益处。

平均随访时间为5.3年，他汀类使用者中死亡人数为271例；对照组5.15年的随访期间内，死亡人数为376例。他汀类药物使用组的死亡率为17.6/1000人年，非他汀类药物使用组的死亡率为25.1/1000人年。

使用他汀类药物治疗与全因死亡率降低32%有关（HR= 0.68）。

研究人员还对非匹配队列进行了比较，以调查倾向得分匹配是否有效。涉及3389名他汀类药物使用者和3389名非他汀类药物使用者，使用他汀类药物可让死亡率增加了44%(HR = 1.44)。

Oza说：“对于病情加重的患者，使用他汀类药物与较高的死亡率有关。”

治疗组和对照组的基线参数相似。研究人员对包括疾病持续时间、社会经济地位、体重指数、生活方式因素和药物使用等50个变量进行多变量分析。

他汀类药物治疗可以降低AS+PsA患者的心血管风险和总死亡率。

原始出处：

Oza A, et al. Abstract #910. Presented at: The American College of Rheumatology Annual Meeting; Nov. 11-16, 2016. Washington.

Statin use linked with reduced mortality among patients with AS and PsA.Healio.November 13, 2016

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082395, encodeId=0e7c20823951f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Aug 17 03:09:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044426, encodeId=c88920444267b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Oct 08 07:09:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156181, encodeId=d328156181ed, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Wed Nov 16 22:30:33 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271056, encodeId=1a6712e10564e, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 16 02:09:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155680, encodeId=9fcf15568013, content=好资料，值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Nov 14 12:03:33 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2017-08-17 ms5353107019656438

    #血管风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2082395, encodeId=0e7c20823951f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Aug 17 03:09:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044426, encodeId=c88920444267b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Oct 08 07:09:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156181, encodeId=d328156181ed, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Wed Nov 16 22:30:33 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271056, encodeId=1a6712e10564e, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 16 02:09:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155680, encodeId=9fcf15568013, content=好资料，值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Nov 14 12:03:33 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2017-10-08 ms6390871039024434

    #他汀类药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2082395, encodeId=0e7c20823951f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Aug 17 03:09:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044426, encodeId=c88920444267b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Oct 08 07:09:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156181, encodeId=d328156181ed, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Wed Nov 16 22:30:33 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271056, encodeId=1a6712e10564e, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 16 02:09:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155680, encodeId=9fcf15568013, content=好资料，值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Nov 14 12:03:33 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-16 大旺旺

    学习了啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2082395, encodeId=0e7c20823951f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Aug 17 03:09:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044426, encodeId=c88920444267b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Oct 08 07:09:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156181, encodeId=d328156181ed, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Wed Nov 16 22:30:33 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271056, encodeId=1a6712e10564e, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 16 02:09:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155680, encodeId=9fcf15568013, content=好资料，值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Nov 14 12:03:33 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-16 zhaozhouchifen

    #PSA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2082395, encodeId=0e7c20823951f, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Aug 17 03:09:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044426, encodeId=c88920444267b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Oct 08 07:09:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156181, encodeId=d328156181ed, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Wed Nov 16 22:30:33 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271056, encodeId=1a6712e10564e, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 16 02:09:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155680, encodeId=9fcf15568013, content=好资料，值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Nov 14 12:03:33 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-14 wxl882001

    好资料，值得学习

    0

相关资讯

IOVS：短期使用他汀类药物可降低青光眼发病率

近期发表在Investigative Ophthalmology & Visual Science的研究称，短期使用他汀类药物与青光眼发病率的下降有关，但是没有发现他汀类药物与眼压（IOP）间的联系。 McCann和同事对七个队列研究进行了分析，以评估他汀类药物的使用和青光眼发病率或进展之间的关联，以及对眼压的影响。其中三个病例对照研究和一个横断面研究，共涉及583615名参与者。

2016AHA科学声明：他汀类和选择性应用心血管疾病的药物之间相互作用的管理建议发布

2016年10月，美国心脏协会(AHA)发布了关于他汀类和选择性应用心血管疾病的药物之间相互作用的管理建议声明，文章回顾了基本药物相互作用，各种他汀类药物的药理作用以及他汀类药物与选择用于治疗心血管疾病药物之间重要的相互作用。针对这些药物相互作用的临床管理提出了建议。全文获取：下载地址：指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

J Intern Med：啥？胰岛素会增加糖尿病患者的癌症风险？

2型糖尿病(T2DM)是否会增加癌症风险，仍不清楚；不同降糖疗法如何影响癌症风险，也不知道。本研究的目的是，提供T2DM治疗、他汀类药物的使用和不同部位癌症间的所有可能联系。 研究纳入1847051例在2006-2007年住院的患者，评估了年龄和性别相关的共同发生的不同部位癌症的诊断与使用降糖药物和他汀类药物之间的联系。 患者用胰岛素或胰岛素促泌素，导致男性结肠癌、肝癌、胰腺癌、肺癌和

Atherosclerosis：高冠脉钙化的患者应服用他汀药物治疗

背景：伴或不伴冠状动脉钙化（CAC）的符合他汀类药物治疗的患者，服用汀类药物治疗的疗效尚不清楚。本研究旨在评估心血管危险因素如何影响应用他汀类药物做为一级预防，及有无他汀类药物治疗CAC修订的临床预后。方法:研究者对圣弗兰西斯心脏研究临床试验进行Post-hoc分析，这项研究是一项双盲、安慰剂对照的随机对照试验，对CAC≥80%的无症状990例受试者每日分别予阿托伐他汀（20mg）、维生素C（1g

Am J Cardiol：部分患者CABG术后没能按照指南推荐服药

根据发表在美国心脏病学杂志数据，近一半的患者接受CABG后，没有采取必要的他汀类药物和阿司匹林治疗。美国心脏协会科学声明建议CABG后使用他汀类药物和阿司匹林作为二级预防长期使用。托马斯杰斐逊大学的Michael P. Savage博士和同事对381名接受诊断性心导管检查术的患者的数据进行了回顾性分析，患者平均年龄69岁，其中男性占78%。数据显示，导管检查时67%的患者服用他汀类药物，75%的患

盘点丨“他汀类药物”的益处多到你想都想不到

他汀类药物是临床上最常见的降胆固醇的处方药，用于治疗和预防各种心血管疾病与高脂血症。这些年关于他汀类药物的研究实在是太多了，他汀类药物对人类健康的益处也实在是太多了，小编就把2016年的相关研究盘点给大家，只是2016年的哦~ 1-FCVB 2016：他汀类药物能降低常见癌症的死亡率吗？ 英国伯明翰阿斯顿大学的研究人员对近100万名患者随访14年后发现，诊断高胆固醇的肺癌患者其死亡

Baidu
map
Baidu
map
Baidu
map